Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)

A hybridoma cell line, monoclonal antibody technology, applied in anti-animal/human immunoglobulin, immunoglobulin, microorganism-based methods, etc., can solve problems such as cardiac troponin deficiency

Active Publication Date: 2017-02-22
KINGS COLLEGE LONDON
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[2] But cardiac troponin (cTn) is defective and new biomarkers could be very valuable
It remains unclear how large the absolute concentration difference must be for the analytical and biological variation of cTn concentrations to be meaningless for prospective diagnostics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)
  • Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)
  • Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Preparation of hybridoma cell lines

[0025] Spleens from mice immunized with cCOC2 of My-C in a known manner were removed under aseptic conditions using RPMI 1640 medium (Life Technologies TM , Karlsruhe) flushed and diluted the splenocytes from the splenic capsule using a syringe. Splenocytes were pelleted (10 minutes, 300xg), washed three times with RPMI 1640 medium, and resuspended in RPMI 1640 medium. Then, it was fused with the myeloma cell line P3X63Ag8.653 (ATTC CPL 1580). For this purpose, cultured myeloma cells in log phase of growth were likewise pelleted and washed three times. Will 1x 10 8 Splenocytes and 5x 10 7 Myeloma cells were pipetted into a centrifuge tube, mixed thoroughly and centrifuged. The centrifuge tube was rotated continuously at 37°C, and 1.Sml of preheated 50% polyethylene glycol 1500 (Roche, Basel) was added dropwise within one minute. into the cell pellet. The fusion reaction was then incubated at 37°C for an additional minute. Pre...

Embodiment 2

[0027] Selection of antibody-producing clones

[0028] All growing clones or their antibodies were tested for reactivity by ELISA (Enzyme-Linked Immunosorbent Assay). The immunosorbent used was the immunogen, recombinant cCOC2 domain of My-C (approximately 2 μg / ml). ELISA protocol:

[0029] 1. Coat a microtiter plate (Costar, high binding capacity) with 50 μl of immunogen solution per well overnight at 4°C;

[0030] 2. Wash the microtiter plate (MTP), wash 3 times with TBS (TRIS-buffered saline) pH 7.4;

[0031] 3. Block MTP, 200 μl blocking agent (Boehringer, Mannheim) per well, 37°C, 1 hour;

[0032] 4. Wash MTP, wash 3 times with NaCl-Tween 20;

[0033] 5. Use the hybridoma culture supernatant to incubate; 50 μl per well, dilute about 1:2 with TBS-Tween 20;

[0034] 6. Wash MTP, wash 3 times with NaCl-Tween 20;

[0035]7. Incubate with peroxycyclase-coupled anti-mouse Ig antibody, 50 μl per well, at room temperature for 1 hour;

[0036] 8. Wash MTP, wash 3 times with...

Embodiment 3

[0040] Epitope mapping of monoclonal antibody 3H8 in human cardiac-specific My-C

[0041] Identification of the binding site of monoclonal antibody 3H8 using a peptide scanning method. To this end, the entire amino acid sequence of the human cCOC2 domain of My-C used for immunization was divided into a total of 111 mutually overlapping amino acid sequences with a length of 15 amino acids. These sequences were synthesized directly on cellulose membranes as individual peptides in spots. The membranes were incubated with antibody-containing hybridoma culture supernatants, and antibody binding sites were visualized by incubation with peroxidase-conjugated anti-mouse Ig antibodies. For this, after three washes with TBS-Tween, the membrane was placed between replica films and then exposed to ECL TM (enhanced chemiluminescence) detection reagent (Amersham, Braunschweig) was incubated for 3 minutes. The film (Hyperfilm-ECL) that will be placed next TM [RPN 2103 HAmersham, Braunsch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The aim of the invention is to produce, in vitro, monoclonal antibodies against cardiac epitopes of the human My-C by generating myeloma cell clones, which produce said specific antibodies with epitope specificity. Said monoclonal antibodies should, amongst other things, enable an ELISA (Enzyme-Linked Immuno Sorbent Assay) for the specific, cross-reactivity free quantitative determination of My-C in serum, plasma or full blood, to be formed. Said aim is achieved by generating a hybridome cell clone which produces a monoclonal antibody which recognizes and binds with a cardiac epitope in the My-C and which does not have the cross-reactivity with respect to the myosin binding proteins of the skeletal muscle. Said hybridome cell line can be obtained by fusing myelome cells with spleen cells of a test animal, in particular a mouse, immunized against recombined My-C. The invention also relates to epitope specific antibodies produced by the hybridome cell lines and to the use thereof.

Description

technical field [0001] The present invention relates to a mouse hybridoma clone that produces a monoclonal antibody (anti-My-C-cCOC2-235-3H8) directed against cardiac myosin binding protein C (C-protein, MYBPC3, cMyBP-C or My-C) ; IgG1, κ), and it does not react with the closely related isoform of My-C from skeletal muscle. This mAb is suitable as a capture or detection antibody for ELISA (enzyme-linked immunosorbent assay) to quantitatively measure My-C in serum, plasma, whole blood or other body fluids for the development of early diagnosis of heart disease. According to this diagnostic procedure, myocardial infarction can be treated earlier. Background technique [0002] Because of the acute life-threatening situation, myocardial infarction must be diagnosed promptly and differentiated from other causes of chest pain. [1] [0003] Measurement of biomarkers of myocardial necrosis is now mandatory for the diagnosis of infarction in suspected NSTE-ACSs (non-ST elevation a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/20C07K16/18G01N33/68C12R1/91
CPCC07K16/18G01N33/6893C07K2317/34G01N2800/324G01N2333/4712C07K16/32C07K2317/14C07K2317/20G01N33/5748
Inventor E·韦伯R·梅德克
Owner KINGS COLLEGE LONDON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap